MX2012005677A - Formulaciones parentales de derivados de gemcitabina. - Google Patents
Formulaciones parentales de derivados de gemcitabina.Info
- Publication number
- MX2012005677A MX2012005677A MX2012005677A MX2012005677A MX2012005677A MX 2012005677 A MX2012005677 A MX 2012005677A MX 2012005677 A MX2012005677 A MX 2012005677A MX 2012005677 A MX2012005677 A MX 2012005677A MX 2012005677 A MX2012005677 A MX 2012005677A
- Authority
- MX
- Mexico
- Prior art keywords
- gemcitabine
- parenteral formulations
- derivatives
- relates
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/09—Pyrimidine radicals with arabinosyl as the saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se relaciona a formulaciones parentales para ciertos derivados de ácidos grasos saturados y monoinsaturados de cadena grande de 2´,2´ difluorodeoxicitidina (Gemcitabina). En particular, la presente invención se relaciona a una composición farmacéutica parental y un método de la preparación de la misma, con el fin de acomodar dosis efectivas terapéuticamente de los derivados que mejoran conformidad en el tratamiento del cáncer. La composición tiene un tamaño de partículas promedio en el intervalo de 2.5-30 nm y contiene típicamente un fosfolipico. Un ingrediente activo preferido es gemcitabina- éster del ácido 5-elaidico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26299909P | 2009-11-20 | 2009-11-20 | |
PCT/NO2010/000417 WO2011062503A1 (en) | 2009-11-20 | 2010-11-15 | Parenteral formulations of gemcitabine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012005677A true MX2012005677A (es) | 2012-08-23 |
Family
ID=43467050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012005677A MX2012005677A (es) | 2009-11-20 | 2010-11-15 | Formulaciones parentales de derivados de gemcitabina. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20110281815A1 (es) |
EP (1) | EP2501364A4 (es) |
JP (1) | JP2013511516A (es) |
KR (1) | KR20120086729A (es) |
CN (1) | CN102740833A (es) |
AU (1) | AU2010322516A1 (es) |
BR (1) | BR112012011784A2 (es) |
CA (1) | CA2778432A1 (es) |
GB (1) | GB201019703D0 (es) |
MX (1) | MX2012005677A (es) |
RU (1) | RU2012125350A (es) |
TW (1) | TW201124425A (es) |
WO (1) | WO2011062503A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013009701A2 (en) | 2011-07-08 | 2013-01-17 | The University Of North Carolina At Chapel Hill | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders |
US20130122096A1 (en) | 2011-11-14 | 2013-05-16 | Silenseed Ltd. | Compositions for drug delivery and methods of manufacturing and using same |
EP2592146A3 (en) | 2011-11-14 | 2013-07-24 | Silenseed Ltd | Methods and compositions for treating prostate cancer |
CN102600077B (zh) * | 2012-03-29 | 2013-06-05 | 江苏豪森药业股份有限公司 | 吉西他滨或其盐纳米乳剂注射液及其制备方法 |
US8889642B2 (en) | 2012-04-19 | 2014-11-18 | Silenseed Ltd. | Methods and compositions for RNAi-based cancer treatment |
WO2014078295A1 (en) | 2012-11-13 | 2014-05-22 | BoYen Therapeutics, Inc. | Gemcitabine prodrugs and uses thereof |
JP6590802B2 (ja) | 2013-11-06 | 2019-10-16 | ザ ユニバーシティ オブ シカゴThe University Of Chicago | 化学療法用薬剤、核酸及び光増感剤の送達又は共送達のためのナノスケール輸送体 |
US10463684B2 (en) | 2014-01-29 | 2019-11-05 | Board Of Regents, The Uneversety Of Texas System | Nucleobase analogue derivatives and their applications |
DK3138555T3 (da) | 2014-04-30 | 2020-12-14 | Fujifilm Corp | Liposomsammensætning og fremgangsmåde til fremstilling heraf |
KR102421929B1 (ko) | 2014-06-25 | 2022-07-15 | 뉴카나 피엘씨 | 젬시타빈-전구 약물 함유 제제 |
LT3160978T (lt) | 2014-06-25 | 2020-08-25 | NuCana plc | Gemcitabino provaistai |
WO2017201528A1 (en) | 2016-05-20 | 2017-11-23 | The University Of Chicago | Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof |
JP2020520961A (ja) | 2017-05-24 | 2020-07-16 | サイレンシード リミテッド | がん免疫療法のための組成物及び方法 |
WO2019028250A1 (en) | 2017-08-02 | 2019-02-07 | The University Of Chicago | NOMOGENEOUS ORGANOMETALLIC ORGANOMETRIC ORGANOMETRIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RODIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF |
CN111107842B (zh) * | 2017-09-22 | 2021-10-08 | 杭州景杰生物科技股份有限公司 | 利用微混合和卡培他滨两亲性特性的卡培他滨的聚合物-脂质混杂纳米颗粒 |
TW202015703A (zh) * | 2018-06-20 | 2020-05-01 | 日商富士軟片股份有限公司 | 包含內含吉西他濱之脂質體組成物及免疫檢查點抑制劑之組合醫藥 |
CN109998996B (zh) * | 2019-05-05 | 2021-02-26 | 中国医学科学院医药生物技术研究所 | 脂质组合物及提高药物抗肿瘤活性的方法 |
CN112898277B (zh) * | 2019-11-19 | 2022-04-22 | 扬子江药业集团有限公司 | 一种阿法替尼中间体的制备方法 |
CN111249252B (zh) * | 2020-03-08 | 2021-09-14 | 中国医学科学院医药生物技术研究所 | 白蛋白纳米粒组合物及其制法 |
CN113307824B (zh) * | 2021-04-26 | 2022-05-27 | 浙江大学 | 一种双亲性材料及其在制备脂质体中的应用 |
EP4248949B1 (en) | 2022-03-21 | 2024-08-28 | R.G.C.C. Holdings AG | Liposomal compositions |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5785976A (en) * | 1993-03-05 | 1998-07-28 | Pharmacia & Upjohn Ab | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof |
GB9515279D0 (en) * | 1995-07-25 | 1995-09-20 | Norsk Hydro As | Improved therapeutic agents |
CA2278056C (en) * | 1997-01-24 | 2006-12-12 | Norsk Hydro Asa | Gemcitabine derivatives |
US6984395B2 (en) * | 2001-04-11 | 2006-01-10 | Qlt, Inc. | Drug delivery system for hydrophobic drugs |
AU2003268087A1 (en) * | 2002-08-23 | 2004-03-11 | Ian Ma | Liposomal gemcitabine compositions for better drug delivery |
WO2010039039A1 (en) * | 2008-10-03 | 2010-04-08 | Clavis Pharma Asa | Oral formulations of gemcitabine derivatives |
-
2010
- 2010-11-15 RU RU2012125350/04A patent/RU2012125350A/ru not_active Application Discontinuation
- 2010-11-15 KR KR1020127015947A patent/KR20120086729A/ko not_active Application Discontinuation
- 2010-11-15 US US13/121,660 patent/US20110281815A1/en not_active Abandoned
- 2010-11-15 EP EP10831847A patent/EP2501364A4/en not_active Withdrawn
- 2010-11-15 CA CA2778432A patent/CA2778432A1/en not_active Abandoned
- 2010-11-15 BR BR112012011784A patent/BR112012011784A2/pt not_active IP Right Cessation
- 2010-11-15 CN CN2010800522764A patent/CN102740833A/zh active Pending
- 2010-11-15 JP JP2012539841A patent/JP2013511516A/ja active Pending
- 2010-11-15 WO PCT/NO2010/000417 patent/WO2011062503A1/en active Application Filing
- 2010-11-15 MX MX2012005677A patent/MX2012005677A/es not_active Application Discontinuation
- 2010-11-15 AU AU2010322516A patent/AU2010322516A1/en not_active Abandoned
- 2010-11-16 TW TW099139312A patent/TW201124425A/zh unknown
- 2010-11-19 GB GBGB1019703.6A patent/GB201019703D0/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2010322516A1 (en) | 2012-05-17 |
CN102740833A (zh) | 2012-10-17 |
WO2011062503A1 (en) | 2011-05-26 |
KR20120086729A (ko) | 2012-08-03 |
CA2778432A1 (en) | 2011-05-26 |
BR112012011784A2 (pt) | 2019-09-24 |
RU2012125350A (ru) | 2013-12-27 |
EP2501364A4 (en) | 2012-10-24 |
US20110281815A1 (en) | 2011-11-17 |
GB201019703D0 (en) | 2011-01-05 |
JP2013511516A (ja) | 2013-04-04 |
EP2501364A1 (en) | 2012-09-26 |
TW201124425A (en) | 2011-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012005677A (es) | Formulaciones parentales de derivados de gemcitabina. | |
SG10201400685SA (en) | Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia | |
MX363023B (es) | Formulaciones orales de analogos de citidina y metodos para usar los mismos. | |
GB2459809A (en) | Fatty acid formulations and methods of use thereof | |
WO2009091538A8 (en) | Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia | |
WO2012079092A3 (en) | Testosterone undecanoate compositions | |
NZ627238A (en) | Stable pharmaceutical composition comprising ethyl eicosapentaenoate | |
MX344476B (es) | Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal. | |
UA90893C2 (ru) | Пероральная дозированная форма производных гемцитабина | |
GB0814302D0 (en) | Compounds and methods | |
NZ618734A (en) | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | |
WO2013016697A3 (en) | 17-hydroxyprogesterone ester-containing oral compositions and related methods | |
MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
WO2012035559A3 (en) | Sustained release pharmaceutical compositions comprising pregabalin | |
NZ591810A (en) | Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid | |
BR112012021337A2 (pt) | formulações de apixaban. | |
MX2012010161A (es) | Metodo para tratar el mal de parkinson. | |
MX2009004980A (es) | Composiciones topicas que comprenden polihidroxi acidos y/o lactonas para efectos cutaneos mejorados de farmacos terapeuticos oxidantes. | |
WO2011116139A3 (en) | Improved pharmaceutical compositions comprising cck- 8 and methods of delivery | |
ZA201005615B (en) | Pharmaceutical compositions of entacapone,levodopa and carbidopa with improved bioavailability | |
NZ596228A (en) | Compositions and methods for the treatment of inflammation | |
UA116334C2 (uk) | Тверді форми дозування бендамустину | |
UA96794C2 (ru) | Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе | |
MY179870A (en) | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis | |
TR201821157T4 (tr) | İbandroni̇k asi̇t veya bunun farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzu ve d vi̇tami̇ni̇ i̇çeren oral uygulamaya yöneli̇k kati bi̇leşi̇m. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |